INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

Core Insights - INmune Bio, Inc. is participating in the Dermatologic Rare Disease Panel at the Maxim Growth Summit on October 22-23, 2025, where CEO David Moss will discuss the company's CORDStrom™ platform for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB) [1][2] Company Overview - INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases [3] - The company has three product platforms: - Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which neutralizes soluble TNF to address immune dysfunction [3] - CORDStrom™, a proprietary platform using human umbilical cord-derived mesenchymal Stromal/Stem cells, which has completed a blinded randomized trial for RDEB [3] - INKmune®, designed to enhance natural killer cells to eliminate minimal residual disease in cancer patients, currently in trials for metastatic castration-resistant prostate cancer [3] Event Details - The Maxim Growth Summit will be held at the Hard Rock Hotel in New York City, with David Moss available for one-on-one meetings throughout the conference [1][2]